Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Common Equity (2016 - 2025)

Arcadia Biosciences' Common Equity history spans 12 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Common Equity fell 33.47% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 33.47%, while the annual FY2025 figure was $4.1 million, 33.47% down from the prior year.
  • Common Equity reached $4.1 million in Q4 2025 per RKDA's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $45.7 million in Q1 2021 to a low of $4.1 million in Q4 2025.
  • Average Common Equity over 5 years is $19.3 million, with a median of $16.0 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 273.91% in 2021, then crashed 60.81% in 2025.
  • A 5-year view of Common Equity shows it stood at $31.2 million in 2021, then tumbled by 33.0% to $20.9 million in 2022, then crashed by 39.22% to $12.7 million in 2023, then crashed by 51.01% to $6.2 million in 2024, then plummeted by 33.47% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Common Equity are $4.1 million (Q4 2025), $5.4 million (Q3 2025), and $4.5 million (Q2 2025).